Premium
Results of the Surveillance Policy of Stage I Non‐seminomatous Germ Cell Testicular Tumours
Author(s) -
COLLS B. M.,
HARVEY V. J.,
SKELTON L.,
THOMPSON P. I.,
DADY P. J.,
FORGESON G. V.,
PEREZ D.J.
Publication year - 1992
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/j.1464-410x.1992.tb15802.x
Subject(s) - stage (stratigraphy) , germ cell , seminoma , andrology , biology , medicine , chemotherapy , genetics , paleontology , gene
Summary— A series of 1 15 patients with clinical Stage I non‐seminomatous germ cell testicular tumours were managed with orchiectomy and close surveillance (median follow‐up 36 months, range 3‐1 19); 34 (29.5%) relapsed, 21 within 6 months, 29 within a year and the latest at 28 months. At relapse all patients were treated with platinum or analogue‐based drug combinations, supplemented in 7 by retroperitoneal node dissection; 30 patients achieved durable remissions and 2 have had further relapses successfully treated. Two died; both had malignant teratoma intermediate with primary stage T1 and vascular and/or lymphatic invasion of primary tumour. At a median follow‐up time of 36 months, the survivors (98.3%) demonstrate no evidence of disease, these results matching the outcome of other methods of management. Vascular and/or lymphatic invasion was associated with an enhanced relapse rate but specific histology, T stage of the primary and pre‐orchiectomy serum alpha‐fetoprotein status did not appear to favour relapse. The first sign of relapse was tumour marker alone in 10 patients, radiological features alone in 12, or both in 10 patients. However, in 2 cases the relapse was first detected clinically. Furthermore, pre‐orchiectomy and relapse marker status did not correlate well. These points emphasise the importance of all aspects of follow‐up, none of which can be safely omitted.